Inhalation administration is a method of delivering drugs directly to target organs (such as the lungs and bronchi) through the respiratory tractRapid onset of action (such as 1-5 minutes during acute asthma attacks), high bioavailability (avoiding first pass effects), high local drug concentration (reducing systemic side effects)It is a core means to treat respiratory diseases (such as asthma, chronic obstructive pulmonary disease COPD) and emerging fields (such as lung infectious diseases, central nervous system diseases). ButDrug inhalation deviceAs a "bridge" connecting drugs with the patient's respiratory tract, its design directly affects the atomization efficiency of drugs, lung deposition rate, and patient compliance. This article will focus on inhalation devicesWorking principle, classification, technological innovationThree dimensions are unfolded to reveal how it promotes inhalation therapy to leap from "experience driven" to "precision intelligent treatment".

1Inhalation deviceThe core working principle of drug delivery: the "triple checkpoint" of drug delivery

The essence of an inhalation device is throughDrug release aerosol generation lung depositionThe three key steps are to convert liquid or solid drugs into inhalable aerosols (particles with a size of 0.5-5 μ m) and ultimately deposit them at respiratory target sites (such as alveoli and bronchi). Its core principles involve the cross application of fluid mechanics, aerosol science, and respiratory physiology.

　　1. Drug release: transition from "stored state" to "dispersible state"​

Drugs are stored in different forms in the device (such as solution, suspension, dry powder) and need to be released into a dispersible state through physical or chemical reactions:

　　Solution/SuspensionIt is necessary to break the surface tension of the liquid through external forces (such as airflow shear, ultrasonic waves) to form tiny droplets (such as the vaporization and expansion of the propellant in the pressure quantitative inhaler pMDI);

　　dry powderIt is necessary to use mechanical force (such as turbine stirring, airflow pulverization) to depolymerize drug crystals into individual particles (such as dispersing lactose carrier in dry powder inhaler DPI);

　　Semi solid/gel: Need to be heated by body temperature or a device (such as a thermal spray inhaler), liquefied and atomized (such as mild delivery of certain biological agents).

　　2. Aerosol generation: screening from "dispersed state" to "inhalable particles"​

After drug release, it needs to be converted into a substance that conforms to the respiratory deposition patternaerosol particle(Particle size is key):

　　Particle size and sedimentary location：

>5 μ m: Impact on the upper respiratory tract (nasal cavity, throat), cleared by mucosal cilia;

2-5 μ m: deposited in the bronchi (the target site for asthma and COPD treatment);

0.5~2 μ m: penetrate deeply into the alveoli (for lung absorption or systemic effects, such as insulin inhalers);

<0.5 μ m: Discharged with exhalation, no therapeutic effect.

　　generation mechanism：

　　Pressure driven(pMDI): The propellant (such as HFA-134a) vaporizes and expands, spraying the liquid at high speed from the nozzle and shearing it into droplets;

　　Airflow driven(DPI): The turbulence generated by the patient's inhalation (flow rate of 15-60L/min) causes the drug particles to disintegrate and disperse through a sieve or Venturi tube;

　　Ultrasonic drive(Nebulizer): Piezoelectric ceramic vibration (1-3MHz) shatters the medicine into droplets (particle size 1-5 μ m);

　　Hot drive(Hot Mist Inhaler): Heat (40-60 ℃) to vaporize the medication, and after cooling, condense into droplets (suitable for thermosensitive drugs).

　　3. Pulmonary deposition: precise delivery from "aerosols" to "target tissues"​

After entering the respiratory tract, aerosols need to overcome the effects of mucociliary clearance (MCC), inertial collision, gravity deposition, etc., and ultimately deposit at the target site:

　　Inertial collisionHigh speed airflow (such as pMDI injection) causes large particles (>5 μ m) to collide with the airway wall;

　　Gravity subsidenceMedium sized particles (2-5 μ m) slowly sink due to gravity and deposit in the bronchi;

　　Brownian motionSmall particles (0.5~2 μ m) deposit in the alveoli due to molecular thermal diffusion;

　　mucociliary clearanceThe cilia of the respiratory mucosa swing to push non deposited particles towards the throat, and after swallowing, they are excreted through the digestive tract (the deposition rate needs to be controlled to prolong the drug's action time).

2、 Main types and technical characteristics of inhalation devices

According to the drug form and driving mode, inhalation devices can be divided intoPressure quantitative inhaler (pMDI), dry powder inhaler (DPI), atomizer (Nebulizer)There are three major categories, each with its own advantages and disadvantages, suitable for different clinical scenarios.

　　1. Pressure Quantitative Inhaler (pMDI): A Portable and Efficient 'Classic Choice'​

　　working principle: WithHydrofluorocarbon (HFA) propellantsUsing (such as HFA-134a, HFA-227ea) as the driving force, the liquid medicine (solution or suspension) is quantitatively sprayed (25-100 μ L/spray) from the pressurized tank and sheared into aerosols (particle size 1-5 μ m) through the nozzle.

　　Technical Features：

Advantages: Portable (palm size), precise dosage (error ≤± 10%), fast onset (1-3 minutes);

Disadvantage: Need to coordinate "pressing+inhaling" (patients need to inhale deeply and press synchronously, children and the elderly are prone to errors); Propellants may induce bronchospasm (rare);

　　Innovation direction：

　　Co suspension technology(such as 3M Aerosphere): By loading drugs onto porous phospholipid particles, the aerosol particle size is made uniform (1-3 μ m), reducing oropharyngeal deposition (from 80% of traditional pMDI to 30%);

　　No projectile design(such as Respimat Soft Mist Inhaler): Using springs to drive the slow release of medication (flow rate 0.8m/s, traditional pMDI is 10m/s), generating finer and more stable aerosols (particle size 1.4-2.8 μ m), reducing the difficulty of hand mouth coordination.

　　2. Dry powder inhaler (DPI): "active inhalation" without the need for propellants​

　　working principle: Medication toDry powder form(Mixed with lactose carrier) stored in capsules or reservoirs, the negative pressure generated by patient inhalation (flow rate of 15-60L/min) causes drug particles to disintegrate and disperse into aerosols (particle size 1-5 μ m) through a sieve or vortex chamber.

　　Technical Features：

Advantages: No need for propellants (environmentally friendly), no need for hand mouth coordination (solely driven by inhalation), suitable for high-dose administration (such as hormone+bronchodilator compound preparations);

Disadvantages: Dependent on patient's inspiratory ability (COPD patients often have insufficient dosage due to respiratory muscle weakness); Medications are prone to moisture absorption and clumping (strict moisture prevention is required);

　　Innovation direction：

　　Carrier optimizationUsing nanoscale porous lactose (such as Novolizer) ® The "star shaped lactose" increases the drug carrier contact area and improves the depolymerization efficiency (lung deposition rate increases from 10% to 20% of traditional DPI to 30% to 40%);

　　Intelligent feedbackIntegrated pressure sensors (such as Turbuhaler) ® The electronic counting device is used to indicate through sound or light that the patient has reached the inhalation standard (flow rate ≥ 30L/min) and correct the patient's incorrect breathing pattern;

　　Multi dose integrationLike Ellipta ® The dual vesicle design (each vesicle containing different drugs) allows for the delivery of two drugs (such as ICS+LAMA) in one inhalation, simplifying the treatment process.

　　3. Nebulizer: Flexible Delivery for Severe Illness and Children​

　　working principle: ThroughCompressed air, ultrasonic or vibrating meshConvert the drug solution (solution or suspension) into an aerosol (particle size 1-5 μ m), which the patient can inhale naturally (without deliberate inhalation).

　　Technical Features：

Advantages: Suitable for infants, elderly or critically ill patients (unable to cooperate with inhalation); Aerosolizable high viscosity drugs (such as acetylcysteine);

Disadvantages: Large size (requiring power), high drug waste (deposition in the oropharynx>50%), slow onset of action (10-20 minutes);

　　Innovation direction：

　　Vibrating mesh atomizer(such as PARI eFlow) ®)： Using metal mesh (aperture 3-5 μ m) with high-frequency vibration (100-200Hz) to generate uniform fine mist (particle size 1.8-2.8 μ m), the drug utilization rate is improved (oropharyngeal deposition is reduced to 20%);

　　Portable ultrasonic atomizer(such as Omron NE-U22): Battery driven (with a range of 2 hours), weighing less than 500g, supporting home/outdoor use;

　　Smart Temperature ControlIntegrated temperature sensor (such as 37 ℃ constant temperature) to avoid respiratory tract irritation from cold air (especially suitable for acute asthma attacks).

3、 Technological innovation: a leap from "effective delivery" to "precise intelligent governance"

With the increasing demand for precision in the treatment of respiratory system diseases (such as personalized dosage, biological agent delivery) and higher compliance requirements from patients, inhalation devices are undergoing changesIntelligent, precise, humanized, and greenFour major technological innovations.

　　1. Intelligence: From "Passive Use" to "Active Guidance"​

　　Respiratory monitoring and feedbackReal time monitoring of patient inspiratory flow rate, volume, and time through built-in sensors (such as differential pressure sensors and accelerometers), and prompting "inspiratory too fast/too slow" (such as "please slow down inspiratory to 30L/min") through the APP or device screen to correct incorrect breathing patterns (research shows that intelligent feedback can increase DPI lung deposition rate by 40%);

　　Dose tracking and remindersIntegrate RFID or Bluetooth modules to record the time and dosage of each medication use. The app synchronously generates a "medication calendar" and pushes reminders in case of missed or excessive use (such as "used twice today, please do not exceed the limit");

　　Remote medical linkageThe data can be synchronized to the doctor's end through the cloud to assist in adjusting the treatment plan (if the patient's inspiratory flow rate is found to be less than 20L/min for a continuous week, it indicates a decline in lung function and requires follow-up).

　　2. Precision: from "extensive delivery" to "targeted deposition"​

　　Precise control of particle size: Produce aerosol with uniform particle size (standard deviation ≤ 0.3 μ m) through microfluidic chips (such as "on-chip atomizer" developed by MIT) or electrostatic spray technology (applying high-voltage electric field to charge the liquid medicine and control particle agglomeration), so as to ensure that more than 90% of particles are deposited on the target (such as pulmonary alveoli);

　　Drug device collaborative designDevelop "mild nebulization" devices (such as low-temperature nebulizers, temperature ≤ 25 ℃) to address the vulnerability of biological agents (such as monoclonal antibodies, mRNA vaccines) and avoid protein denaturation (traditional nebulizers with temperature>40 ℃ may cause antibody inactivation);

　　Multi compartment dosing technologyFor example, the "dual chamber nebulizer" (one chamber containing bronchodilators and the other containing hormones) uses an electromagnetic valve to control the sequential nebulization, achieving a sequential treatment of "expanding the airway first, then delivering hormones", and improving the efficacy.

　　3. Humanization: From "Function First" to "Experience First"​

　　Child friendly designUsing cartoon shapes (such as teddy bears and cars), fun sound effects (such as "successful inhalation" playing music), and low resistance inhalation valves (flow rate requirement<15L/min) to reduce children's resistance psychology;

　　Elderly friendly designIncrease button/scale markings (font ≥ 5mm), simplify operation steps (such as "one click start" atomizer), voice navigation ("please take a deep breath, hold for 5 seconds"), and reduce operational errors;

　　Improved portabilityMiniature design (such as reducing the volume of pMDI by 30%), lightweight materials (such as carbon fiber), long battery life (atomizer life>8 hours), and support for outdoor carrying.

　　4. Greening: From "Chemical Driven" to "Environmentally Friendly"​

　　No propellant substitutionPMDI is gradually phasing out fluorocarbons (CFCs) and HFA (with high greenhouse gas potential GWP) and shifting towards "co suspension technology" or "soft fog devices" (such as Respimat, whose GWP is only 1/100 of HFA);

　　recyclable materialsThe main body of the device is made of biodegradable plastic (such as PLA) or recycled plastic (PCR) to reduce carbon emissions (such as reducing the carbon footprint of a certain brand of DPI shell by 60% after recycling);

　　Drug saving designBy precise dose control (such as reducing the minimum spray volume of pMDI from 25 μ L to 10 μ L), reducing oropharyngeal deposition (such as co suspension technology), and reducing drug waste (reducing the annual dosage of a single patient by 20% to 30%).

4、 Future Trends: Cross border and Integration of Inhalation Therapy

The technological innovation of inhalation devices is driving them from being "respiratory system specific medical devices" toCross system disease treatment platformexpand:

　　Neurological disordersTargeted delivery of drugs to the brain, such as Parkinson's disease and Alzheimer's disease (through the rich capillary network in the lungs, drugs are absorbed by the alveoli and enter the systemic circulation, breaking through the blood-brain barrier);

　　tumor therapyLocal chemotherapy for lung cancer (aerosol particles carrying chemotherapy drugs directly deposited at the tumor site to reduce systemic toxicity);

　　Vaccine deliveryInhalation vaccination of mRNA (simulating respiratory infections, stimulating mucosal immunity, and enhancing protection).

　　ConclusionThe working principle of the drug delivery inhalation device is the crystallization of interdisciplinary wisdom, and its technological innovation always revolves around "improving drug delivery efficiency, improving patient compliance, and expanding treatment boundaries". From classic pMDI to intelligent DPI, from nebulizers to cross system delivery platforms, the speed of inhalation devices has propelled inhalation therapy into a new era of "precision, intelligence, and universal", providing revolutionary solutions for the treatment of respiratory and other difficult to treat diseases.